iBio, Inc. (NASDAQ:IBIO) Receives $4.75 Average PT from Analysts

iBio, Inc. (NASDAQ:IBIO) has been assigned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $4.75.

A number of analysts have recently commented on the company. Lifesci Capital raised iBio to a “strong-buy” rating in a research report on Thursday, December 18th. Chardan Capital reissued a “buy” rating and issued a $5.00 price target on shares of iBio in a research report on Wednesday, March 18th. JonesTrading assumed coverage on iBio in a research report on Tuesday, March 3rd. They issued a “buy” rating and a $7.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research report on Friday, March 27th. Finally, Wall Street Zen raised iBio from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th.

iBio Stock Performance

iBio stock opened at $2.24 on Monday. The firm’s 50 day moving average price is $2.30. The company has a market cap of $77.37 million, a PE ratio of -2.24 and a beta of 1.36. iBio has a fifty-two week low of $0.56 and a fifty-two week high of $3.82.

iBio (NASDAQ:IBIO) last posted its quarterly earnings data on Tuesday, February 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01).

Insider Activity at iBio

In related news, CFO Felipe Duran purchased 24,835 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were purchased at an average cost of $2.02 per share, with a total value of $50,166.70. Following the transaction, the chief financial officer directly owned 35,974 shares in the company, valued at $72,667.48. This trade represents a 222.96% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.75% of the stock is currently owned by corporate insiders.

Institutional Trading of iBio

A number of hedge funds have recently made changes to their positions in IBIO. Susquehanna International Group LLP bought a new stake in shares of iBio in the 3rd quarter worth approximately $37,000. PFG Investments LLC bought a new position in iBio in the 4th quarter valued at approximately $41,000. XTX Topco Ltd bought a new position in iBio in the 4th quarter valued at approximately $71,000. Persistent Asset Partners Ltd bought a new position in iBio in the 4th quarter valued at approximately $76,000. Finally, Citadel Advisors LLC bought a new position in iBio in the 3rd quarter valued at approximately $109,000. 7.90% of the stock is owned by institutional investors.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.